The long awaited results of the new dementia drug have been presented

At the annual ‘Clinical Trials on Alzheimer’s Disease’ meeting in San Francisco, the progress of the latest research has been made public. The attention was particularly on the new drug ‘Lecanemab’ and it’s ‘slow down’ effects on people in the early stages of Alzheimer’s. See the BBC article “Alzheimer’s drug lecanemab hailed as momentous breakthrough“.